NKCx Histopathological outcome* within 12 months after cervix cytology in 2018 |
531 Skövde |
Benign | CIN1 | CIN2 | CIN3 | AIS | Cancer | Other | PAD missing | Total | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytology | Count | Pct | Count | Pct | Count | Pct | Count | Pct | Antal | Andel | Count | Pct | Count | Pct | Count | Pct | Count | Pct |
Benign sample | 80 | 0.5% | 5 | 0.0% | . | . | . | . | . | . | . | . | 2 | 0.0% | 15438 | 99.4% | 15525 | 100.0% |
ASCUS | 59 | 13.6% | 41 | 9.4% | 1 | 0.2% | 49 | 11.3% | . | . | 1 | 0.2% | . | . | 284 | 65.3% | 435 | 100.0% |
CIN1 | 39 | 22.9% | 28 | 16.5% | 1 | 0.6% | 53 | 31.2% | 2 | 1.2% | 1 | 0.6% | 1 | 0.6% | 45 | 26.5% | 170 | 100.0% |
Atypical glandular cells/AGC | 6 | 50.0% | 3 | 25.0% | . | . | 2 | 16.7% | . | . | 1 | 8.3% | . | . | . | . | 12 | 100.0% |
ASC-H | 5 | 12.2% | 1 | 2.4% | . | . | 27 | 65.9% | 1 | 2.4% | 2 | 4.9% | 1 | 2.4% | 4 | 9.8% | 41 | 100.0% |
CIN3 | 6 | 18.8% | 3 | 9.4% | . | . | 21 | 65.6% | . | . | 2 | 6.3% | . | . | . | . | 32 | 100.0% |
Total | 195 | 1.2% | 81 | 0.5% | 2 | 0.0% | 152 | 0.9% | 3 | 0.0% | 7 | 0.0% | 4 | 0.0% | 15771 | 97.3% | 16215 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (CIN1) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |